
Sudeep Pharma IPO enters the second day of bidding today on November 24, 2025. The bidding window will remain open till November 25, 2025, and the allotment process is expected to be finalised the following day, i.e., November 26, 2025.
Sudeep Pharma Ltd is a manufacturer of excipients and speciality ingredients for the pharmaceutical, food, and nutrition industries. The shares of Sudeep Pharma Ltd will be listed on both NSE and BSE with a tentative listing date of November 28, 2025.
Sudeep Pharma's IPO is a book-building issue of ₹895 crores. The issue comprises a fresh issue of 0.16 crore shares aggregating to ₹95 crores and an offer for sale (OFS) of 1.35 crore shares aggregating to ₹800 crores. The IPO price band is set between ₹563 and ₹593 per share. The lot size for an application is 25, and the minimum amount of investment required by a retail investor is ₹14,825 (25 shares) based on the upper price.
ICICI Securities Limited and IIFL Capital Services Limited (formerly known as IIFL Securities Limited) are the book-running lead managers for the IPO. MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited) is the registrar for the issue.
[November 24, 2025, 10:42 AM]
On Day 2 of subscription, Sudeep Pharma Ltd saw a subscription of 2.35 times as per the NSE data on November 24, 2025, 10:42 a.m. The public issue was subscribed 2.43 times in the Retail Individual Investors (RIIs) category, 5.17 times in the Non Institutional Investors (NII) category and 0.10 times in the Qualified Institutional Buyers (QIBs) category.
Explore other Upcoming IPOs on BSE and NSE.
The Company will utilise the net proceeds from the fresh issue for the following purposes:
Check out newly Listed IPOs on BSE and NSE.
Sudeep Pharma Limited, incorporated in December 1989 and headquartered at Vadodara, Gujarat, is a manufacturer of mineral-based excipients and speciality ingredients serving the pharmaceutical, food and nutrition industries. The company’s product range includes calcium, magnesium, iron, zinc, potassium and sodium derivatives used as functional ingredients and excipients.
It operates manufacturing facilities in Vadodara (Gujarat) and exports to a vast global base. For the fiscal year ended December 31, 2024, Sudeep Pharma reported revenue from operations of about ₹ 344.45 crore and a net profit of approximately ₹ 94.54 crore.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here